Cryoport: Picks And Shovels For The Gene Therapy Boom [Seeking Alpha]
CryoPort, Inc. (CYRX)
NASDAQ:AMEX Investor Relations:
ir.cryoport.com
Company Research
Source: Seeking Alpha
CYRX supports 745 clinical trials and 19 commercial therapies, with commercial segment revenue up 36% YoY, reflecting accelerating industry adoption. Despite strong growth and a dominant market position, CYRX trades at depressed valuations, offering a deep value opportunity for patient investors. Cryoport's $255.8 net cash position accounts for ~53% of its $481M market capitalization, giving it a formidable balance sheet that is buffered from downside risks. STAP/E+ via Getty Images Intro In an era where cell and gene therapies (CGT) are transitioning from scientific promises to clinical realities, one of the most undervalued plays lies in the underlying infrastructure enabling the growth in these technologies. Cryoport, Inc. ( This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of CYRX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not re
Show less
Read more
Impact Snapshot
Event Time:
CYRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYRX alerts
High impacting CryoPort, Inc. news events
Weekly update
A roundup of the hottest topics
CYRX
News
- CryoPort (NASDAQ:CYRX) had its "sell (d)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- How the Story Behind Cryoport Is Evolving After Recent Analyst and Market Developments [Yahoo! Finance]Yahoo! Finance
- CryoPort (NASDAQ:CYRX) had its "buy" rating reaffirmed by analysts at UBS Group AG.MarketBeat
- CryoPort (NASDAQ:CYRX) had its price target raised by analysts at Needham & Company LLC from $11.00 to $12.00. They now have a "buy" rating on the stock.MarketBeat
- Cryoport Reports Third Quarter 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
CYRX
Earnings
- 11/4/25 - Beat
CYRX
Sec Filings
- 11/12/25 - Form SCHEDULE
- 11/6/25 - Form 10-Q
- 11/4/25 - Form 8-K
- CYRX's page on the SEC website